Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652162 | 0.86 | ACHE (0.52) | ACHEALDH1A1CXCR4FAAHKMT2A | |
| SCHEMBL19658602 | 0.86 | CXCR4 (0.59) | ACHEALDH1A1CXCR4DRD4 | |
| SCHEMBL19658384 | 0.86 | ATM (0.55) | ACHEALDH1A1KMT2ADRD4 | |
| SCHEMBL28003062 | 0.84 | ACHE (0.58) | ACHEALDH1A1CXCR4KMT2ADRD4 | |
| SCHEMBL19658479 | 0.83 | ACHE (0.76) | ACHE | |
| SCHEMBL17753659 | 0.81 | ACHE (0.57) | ACHEALDH1A1CXCR4FAAHKMT2A | |
| SCHEMBL17753009 | 0.79 | ACHE (0.60) | ACHEKMT2A | |
| SCHEMBL14492295 | 0.78 | ACHE (0.69) | ACHEALDH1A1CXCR4FAAHKMT2A | |
| SCHEMBL19658389 | 0.78 | ACHE (0.58) | ACHEALDH1A1CXCR4FAAHKMT2A | |
| SCHEMBL19658385 | 0.76 | ACHE (0.60) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | ACHE 2649/4885ALDH1A1 1563/4885CXCR4 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.